1. Patients & Methods 2012 December ~ 2013 December
Institutions: Inha University Hospital, Severance Hospital, Ilsan Hospital
N=61 cases (56 patients)
Inclusion criteria
Age 18~65
High-energy foot & ankle Fx
61 cases (56 patients)
Calcaneus: 27
Trimalleolar: 22
Pilon: 9
Talus & distal tibia: 3
Control group (n=32)
Conventional gauze dressing
Test group (n=29)
Dressing with Incisional NPWT

2. Application
-125 mmHg
Continuous mode
Duration : 72hrs

3. Vascular problem (Bleeding tendency)
Demographic Data
NPWT (N=29)
Control (N=32)
P value
Smoking
9 (31%)
12 (37.5%)
0.74
Alcohol
14 (48.2%)
18 (56.2%)
0.92
Diabetes
5 (17.2%)
3 (9.4%)
0.95
HTN
6 (20.7%)
8 (25%)
0.81
Vascular problem (Bleeding tendency)
1 (3.4%)
1 (3.1%) 1
Mean BMI
23.22
24.95
0.58
Incision length(cm)
14.2
14.6
0.46

4. Distribution of Fracture Type
NPWT (N=29)
Control (N=32)
Total
Trimalleolar
9 (31%)
13 (40.6%)
22 (36.1%)
Pilon
5 (17.2%)
4 (12.5%)
9 (14.7%)
Calcaneus
14 (48.3%)
27 (44.3%)
Talus and distal
Tibia Fx.
1 (3.4%)
2 (6.2%)
3 (4.9%)

5. Initial Application
Cases
Control
Incisional NPWT

6. Postoperative Day 1
Control
Incisional NPWT

7. Postoperative Day 3
Control
Incisional NPWT

8. Postoperative Day 14
Control
Incisional NPWT

9. Complications Associated with The Dressings - maceration, erythema, skin irritation sign
(Complications: maceration, erythema, skin irritation sign)
NPWT (N=29)
Control (N=32)
P value
POD 1d 5 10
0.342
POD 3d 9
0.468
POD 14d 1 2
0.42

10. Final Results at Postoperative Day 14
NPWT (N=29)
Control (N=32)
P value
Infection 3
0.146
Dehiscence 5
0.035
Cosmetic evaluation
7.31/10
6.23/10
0.23

11. Swelling Reduction Effective in rapid decrease of swelling
Mild
Moderate
Severe
Pre-OP
P = 0.005
: Repeated measured 2- way ANOVA test
Effective in rapid decrease of swelling
Effective in rapid decrease of swelling

12. Trial Summary Effects of Incisional NPWT Conclusion
Decreases swelling more rapidly (p<0.05).
Reduces wound dehiscence (p<0.05).
Effects on Postop wound infection
– Show reduction but not statistically significant
Conclusion
Helpful in reducing postoperative wound problems in high energy foot & ankle trauma.

13. On-Going Clinical TrialsNo
Product
Indication
Study duration
Target
Enrolled
Progress 1
KulaVAC
DM foot 20 16
80% 2 50 37
74% 3 10 7
70% 4
Pressure Ulcer 30 19
63% 5
Incisional Wound
100% 6 0% 8
40% 9
KulaVAC-Silver 22
86%
91% 11 21
95% 12
KulaVAC-Bridge
25% 13
Burn ND 14
KulaVAC + CGDerm
FTSG 15
Trauma
10% 17
Donor site 40 18

14. KulaVAC® Marketing Representative
in China
 Daewoong Pharmaceutical Co.,Ltd. China
 金正煥 (Kim Jung Hwan)
 Tel :
 Fax :
 Mobile : (CHI) ,
(KOR)  
     
Room 2208B, East Tower of Twin Towers, No.B12, JianGuoMen Wai Avenue,  ChaoYang District, Beijing, China 北京市朝阳区建国门外大街乙十二号双子座大厦东塔2208B

15. Thank you

16. KulaVAC® Publications